In addition, there are several other therapeutic approaches regarding use of ACC inhibitors, fructose inhibitors and obetocholic acid inhibitors (188, 190) for the treatment of NAFLD. Here, ACACA is linked to metabolic dysfunction-associated steatotic liver disease.